COPENHAGEN, May 13 (Reuters) -

Denmark faces a supply shortage for two doses of Novo

Nordisk's Wegovy weight-loss drug in the coming

months due to rising demand, the Danish Medicines Agency said on

Monday.

The hugely popular Wegovy is given by weekly injection

and belongs to a class of drugs known as GLP-1 agonists

originally developed to treat type 2 diabetes.

There will be a shortage of Novo Nordisk's Wegovy

Flextouch 1 milligram pen from late May to mid-June, the Danish

medicines agency said in a statement.

There will also be a shortage of Novo's 0.5 mg Wegovy

Flextouch pen between mid-June and mid-July, it added.

Novo Nordisk did not immediately respond to a request for

comment.

Increasing demand for GLP-1 agonists, highly effective

diabetes and weight-loss treatments, has led to supply

constraints for drugmakers such as Eli Lilly ( LLY ) and Novo

Nordisk.

Novo's weekly Wegovy injections start at 0.25 mg of active

ingredient semaglutide and gradually increase to the maintenance

dose of 2.4 mg.

In addition to controlling blood sugar, the drugs affect

hunger signals to the brain and slow the rate at which a

person's stomach empties, making them feel full longer.